×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
Business Wire
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for...
1 week ago
Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year ...
Yahoo Finance
Based on this FY 2024 forecast, Poxel expects that TWYMEEG net sales can also reach JPY 10 billion (EUR 61.2 million)3 which would lead Poxel to...
3 weeks ago
Poxel to Report Its 2023 Annual Results by the End of April 2024
Yahoo Finance
LYON, France, March 28, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company...
1 month ago
Poxel Provides Corporate Update
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic...
5 months ago
French First-in-Class Diabetes Drug Nails Phase III Trial
Labiotech.eu
An oral first-in-class drug, developed by the French biotech Poxel to target multiple organs simultaneously, has shown big potential for...
22 months ago
Poxel's PXL770, PXL065 receive EC orphan drug designation
Pharmaceutical Technology
Poxel SA · View all. PXL770 is a new, first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK). It has been...
15 months ago
Ahead of possible Japanese approval, Metavant backs away from Poxel-partnered imeglimin
Fierce Biotech
Metavant is giving up on experimental diabetes therapy imeglimin and is looking to sell the unwanted med on.
42 months ago
Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia
Reuters
Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia ... * RECEIVES FUTURE POTENTIAL DEVELOPMENT MILESTONE...
78 months ago
Roivant-Poxel-join-imeglimin
Chemical & Engineering News
Advertisement ... The structure of imeglimin. Roivant Sciences, an investment vehicle of biotech investor Vivek Ramaswamy, will put $50 million...
75 months ago
Poxel reports positive type 2 diabetes data for Imeglimin
Clinical Trials Arena
Poxel and its partner Sumitomo Dainippon Pharma have reported results from the Phase III TIMES 1 trial of Imeglimin in type 2 diabetes...
61 months ago